Atai Life Sciences B.V. Stock Price, News & Analysis

atai Life Sciences (Nasdaq: ATAI) announced a webcast on March 30, 2022, at 8:30 AM ET to discuss its fourth quarter 2021 financial results and provide a business update. The live and archived webcast can be accessed through this link. Founded in 2018, atai focuses on innovative therapeutics for mental health disorders like depression and anxiety.

atai Life Sciences (Nasdaq: ATAI), a clinical-stage biopharmaceutical company focused on mental health treatment, will participate in two investor conferences in March 2022. The first is the Citi Winter Biotech Virtual Bus Tour on March 22, from 11:00 a.m. to 11:40 a.m. ET. The second is the Maxim Group 2022 Virtual Growth Conference, occurring from March 28 to March 30. Archived webcasts will be accessible via the Events section on atai's website.

atai Life Sciences has announced a $500,000 donation to the Multidisciplinary Association for Psychedelic Studies (MAPS) through its philanthropic arm, atai Impact. This funding will support MAPS' operations and its Health Equity Program, aimed at increasing diversity and inclusivity in psychedelic healthcare. The donation reflects a collaborative effort to address the global mental health crisis worsened by the pandemic. Florian Brand, CEO of atai, emphasized the importance of innovation and collaboration in tackling these challenges.

atai Life Sciences N.V. (Nasdaq: ATAI) will participate in the Aegis Conference on February 24, 2022, at 11:30 a.m. ET. The conference will be virtual, and interested parties can access the presentation via this link.

Founded in 2018, atai focuses on innovative therapeutics for mental health disorders, including depression and anxiety. Their approach emphasizes psychedelics and drugs with unique safety profiles, aiming to expedite the development of effective treatments.

Atai Life Sciences announced FDA clearance for a clinical drug-drug interaction study on PCN-101 (R-ketamine), aimed at treating treatment-resistant depression (TRD). The study will assess pharmacokinetics when used with other medications and will complement an ongoing Phase 2a trial in Europe. PCN-101 offers potential rapid action and better safety compared to traditional antidepressants. An estimated 100 million people globally suffer from TRD, leading to increased healthcare costs. The study reflects atai's commitment to addressing significant mental health needs.

atai Life Sciences (Nasdaq: ATAI), a leader in mental health treatment innovation, will participate in the H.C. Wainwright BioConnect Conference on January 10, 2022, at 2:00 p.m. ET. The presentation will take the form of a Fireside Chat and can be accessed via a webcast link. Founded in 2018, atai focuses on developing therapies for mental health disorders, including depression and anxiety. With offices in New York, London, and Berlin, atai aims to address the unmet needs in mental health treatment by harnessing innovative therapeutics.

atai Life Sciences has launched the atai Fellowship Fund in Psychedelic Neuroscience, a $2 million initiative aimed at advancing research on the therapeutic potential of psychedelics for mental health. In collaboration with Massachusetts General Hospital, this fellowship will support graduate students focused on diversity, equity, and inclusion. The program aims to unlock new treatments for mental health disorders affecting over a billion people globally, while fostering a new generation of neuro-innovators.

atai Life Sciences (Nasdaq: ATAI) announced voluntary lock-up agreements by key shareholders, including Apeiron Investment Group, extending trading restrictions for 24 months. This represents over 30% of atai’s outstanding shares, indicating strong investor confidence in its innovative platform to address mental health issues. The renewed commitments signal a long-term belief in atai's mission to transform mental health treatment. The company's focus is on developing new therapies for mental health disorders, leveraging its unique business model to accelerate drug development.

atai Life Sciences announced positive topline data from its Phase 2a study of RL-007 for Cognitive Impairment Associated with Schizophrenia (CIAS). The 32-patient trial demonstrated a clinically meaningful pro-cognitive profile and changes in quantitative electroencephalogram (qEEG) consistent with prior results. Notably, dose-related improvements were observed in cognitive endpoints, including the Symbol Coding Test. The findings support advancing RL-007 to a double-blind, placebo-controlled Phase 2 trial, addressing the significant unmet need for CIAS treatments, which currently lack approved options.